FLT3 and acute myeloid leukemia: Synergy was observed between midostaurin coupled with venetoclax, navitoclax or S63845; the panel of wt FLT3‐expressing human AML cell lines we tested included those showing either high sensitivity or relatively high resistance to venetoclax as a single agent as has been previously reported.39 We generally observed some combinations between midostaurin and standard chemotherapeutic agents to show stronger synergy than others, with comparatively weaker combination effects observed for the simultaneous administration of midostaurin+ Ara‐C against both mutant FLT3‐ and wt FLT3‐expressing cells.